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Malignant giant solitary fibrous tumor (SFT) of the mediastinum is
a rare neoplasm derived from mesenchymal tissue. Owing to its
large size, a complete resection of the tumor can present many
challenges, particularly given its proximity to vital neighboring
structures. We report a successful en-bloc resection of a massive
mediastinal SFT, which was compressing the inferior trachea and
heart, by means of a median sternotomy and an anterior left
thoracotomy. We emphasize the rarity of this uncommon mediasti-
nal mass. Key points of mediastinal SFT are discussed.
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CASE REPORT
A 64-year-old man presenting with a mediastinal mass wasreferred to our hospital. Subsequent to a chest x-ray and
computed tomography (CT), a diagnostic work-up revealed a
large anterior mediastinal mass (142  106 mm) extending
from the confluence of the brachiocephalic veins to the
diaphragm. It significantly displaced both the carina and the
heart posteriorly. Moreover, the mass displayed a marked
heterogenicity suggestive of necrosis (Figure 1). No pleural
effusion or significant lymph nodes were noticeable. Trans-
thoracic echocardiography showed a mass that extrinsically
compressed the right ventricle outflow tract, causing pulmo-
nal valve pseudo-stenosis (maximal gradient of 31 mmHg).
Positron emission tomography (PET) with [18fluorine]fluoro-
deoxyglucose (FDG) showed a large heterogenic hypermeta-
bolic area in the anterior mediastinum. A CT-guided trans-
cutaneous aspiration biopsy was preoperatively performed
and was compatible with a tumor of mesenchymal origin. The
histologic and immunohistochemical profile suggested that
the mass was a solitary fibrous tumor (SFT). The patient
underwent surgical resection, using combined median ster-
notomy and anterior left thoracotomy (Figure 2). The tumor
appeared to arise from the mediastinal pleura on the left side.
There was no invasion of vital neighboring structures or
strong adherence to other mediastinal structures. The excised
specimen measured 17.5 cm  14 cm  10 cm.
Immunohistochemical analysis of the tumor cells
showed consistent positive staining for smooth muscle actin,
Bcl-2, cluster of differentiation 99 (CD99), and CD34; neg-
ative staining of the tumor cells was shown for low molecular
weight cytokeratin (CAM 5.2), cytokeratin (KL1), S100,
desmin, (CD31), chromogranin, and synaptophysin. How-
ever, an unusual histologic pattern of SFT was noted (i.e.,
tissue necrosis, focal increased mitotic activity of more than
4 mitoses per 10 high power field, high cellularity, large
tumor size (175 mm), and no strong pleiomorphic tumor
cells), which led to the classification of the tumor as a
malignant giant SFT of the mediastinum (Figures 3 and 4).
Focally, the tumor reached the surgical margin of the medi-
astinal pleura on the left side. Fluorescence in situ hybridiza-
tion analysis showed an absence of the t(X;18) translocation,
which ruled out the presence of synovial sarcoma.
After multidisciplinary deliberation, our patient under-
went adjuvant radiotherapy (a cumulative dosage of 60 Gy in
30 fractions of 2 Gy), given that the tumor focally reached the
surgical margin. The patient is doing well 1 year after
surgery, with a stable body weight. Semi-annual radiologic
follow-ups (CT scan and FDG-PET) have shown no signs of
recurrence.
DISCUSSION
SFTs (so-called fibrous mesotheliomas) are rare pri-
mary neoplasms in adults. They typically present as intratho-
racic pleural-based lesions. Approximately 1 to 8% of these
intrathoracic tumors have been reported to occur in the
mediastinum. The frequency of mediastinal localization is
identical in both men and women. The tumor generally
develops between the fifth and seventh decades. Fortuitous
discovery governs the success of treatment. Benign forms of
the tumor are three- to four-times more common than the
malignant forms. Although the pathogenesis is obscure, the
currently accepted theory is a derivation from submesothelial
mesenchymal cells with fibroblastic differentiation.1–3
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The histologic features of SFTs mainly demonstrate 2
patterns (i.e., patternless and prominent vascularity). Immu-
nohistochemically, SFTs commonly express CD34, CD99,
and Bcl-2; epithelial membrane antigen and smooth muscle
actin may also be expressed. They are usually negative for
S-100 protein, desmin, and cytokeratins. These findings sup-
port the currently favored view that SFTs are composed of
submesothelial mesemchymal cells. Pathologic criteria of
malignancy include a large tumor size (more than 50 mm),
infiltrative margins, high cellularity, nuclear pleiomorphism,
an area of tissue necrosis, and an increased mitotic index
(more than 4 mitoses in 10 high power field)1–4; these criteria
were observed in the tumor from our patient. Differential
diagnoses of SFTs are extensive and consist of epithelioid
sarcoma, schwannoma, leiomyosarcoma, malignant periph-
eral nerve sheath tumor, hemangiopericytoma, and synovial
sarcoma, among others.5
The clinical behavior of this tumor is unpredictable. Signs
and symptoms, if any, are usually associated with larger tumors
and occur more frequently in malignant subtypes. Symptoms are
the result of either local compression/invasion of adjacent tho-
racic structures (e.g., dyspnea, angina, and/or cough) or para-
FIGURE 1. Thoracic CT scan showing an anterior mediasti-
nal mass of heterogeneous density.
FIGURE 2. Combined median sternotomy and left anterior
thoracotomy for removal of a giant mediastinal solitary fi-
brous tumor.
FIGURE 3. Light photomicrograph of a malignant giant
solitary fibrous tumor of the mediastinum showing signs of
tissue necrosis (arrows).
FIGURE 4. Light photomicrograph of a malignant giant
solitary fibrous tumor of the mediastinum showing focal in-
creased mitotic activity (4 mitoses/10 HPF) (arrows).
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neoplastic syndromes (e.g., hypoglycemia, weight loss, and/or
pulmonary osteoarthropathy).1,2
The diagnostic and prognostic criteria for mediastinal
tumors are identical to those for localized fibrous tumors of
the pleura. Tissue is required for diagnosis. The accurate
diagnosis of SFT is aided by ancillary techniques such as
immunohistochemical staining. A preoperative diagnosis of
SFT based on radiologic imaging can be difficult, and differ-
entiation between malignant and benign forms is often im-
possible by CT or magnetic resonance imaging. The diagnos-
tic accuracy of a CT-guided aspiration biopsy has been shown
to be poor and may not be helpful in making the decision
about the need for surgery. A CT-guided aspiration biopsy
may be helpful in cases where the diagnosis of SFT is
uncertain. To date, there are few reports of a FDG-PET
performed in patients with these tumors. FDG-PET could
possibly predict or preoperatively rule out malignancy in a
SFT and may reveal metastatic recurrence, an event rarely
observed in these tumors. Large SFTs with increased FDG-
uptake have a likelihood for malignancy, but the role of a
FDG-PET in clinical practice must be further defined.1,6
The treatment of choice for SFT is extensive surgical
resection. Surgical excision is curative for most benign le-
sions; however, malignant lesions will often recur and
progress despite adjuvant radiation or chemotherapy. The
most important indicator of the clinical outcome is whether or
not the tumor can be totally excised in the initial operation. In
the case of a recurrence, a surgical resection offers the best
chance for a complete cure. Few cases using adjuvant radio-
therapy or chemotherapy in malignant SFT have been re-
ported, and the effectiveness of radiation and chemotherapy
has not been proven.1,2,6
In conclusion, a long-term clinical follow-up is recom-
mended for all patients with a SFT because of its potential
adverse biologic behavior that could lead to repeated recur-
rences and/or malignant transformation. The behavior of a
SFT is unpredictable, and the relationship between morphol-
ogy and outcome is poor. For example, some “malignant”
tumors behave as if benign, whereas morphologically “be-
nign” lesions sometimes are aggressive in nature. In addition
to the presence of histologic criteria of malignancy, an ab-
sence of sclerotic-hypocellular areas and a tumor size of more
than 10 mm have been considered predictors of a poor
outcome. The local recurrence or onset of metastases depends
on histologic parameters. In cases of a benign classification
(60–80%), the recurrence rate was only 2% after surgical
excision. Approximately half of patients with a malignant
SFT can be cured, whereas the rest often develop recurrences
and metastases. In the latter cases, emphasis should be placed
on continual follow-up examinations. If recurrence occurs in
benign lesions, it may be due to incomplete resection, an
unrecognized malignancy, or the growth of an unrelated
second SFT. A follow-up plan after resection of a malignant
SFT should include semi-annual radiologic controls by CT in
the first 2 years, and this should be performed on a yearly
basis thereafter. A long-term follow-up is mandatory in the
case of malignant lesions because of possible late recur-
rences; these can be locally aggressive and may lead to death
through local invasion and compression.1,4,7,8
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